model,flat_path,key_cat,val_cat,ref_val,pred_val,val_match,sim,score_status,piece,norm_path,from_pred,in_ref,in_pred,type_mismatch,is_enum,sim_failed
Claude-4.5-Sonnet,protocolSection.identificationModule.nctId,TP,TP,NCT02861014,NCT02861014,True,1.0,exact,NCTId,protocolSection.identificationModule.nctId,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.briefTitle,TP,TP,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies,True,0.99,success,BriefTitle,protocolSection.identificationModule.briefTitle,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.officialTitle,TP,TP,An Open-Label Study To Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Multiple Sclerosis Who Have A Suboptimal Response to an Adequate Course of Disease-Modifying Treatment,"Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial",True,0.97,success,OfficialTitle,protocolSection.identificationModule.officialTitle,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.acronym,EV,EV,,CASTING,,,,Acronym,protocolSection.identificationModule.acronym,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.descriptionModule.briefSummary,TP,TP,"The purpose of this prospective, multicenter, open-label, efficacy, and safety study is to assess the efficacy and safety of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS) who have had a suboptimal response to an adequate course of a Disease-Modifying Treatment (DMT). The study will consist of a Screening period (up to 4 weeks), an Open-label treatment period (96 weeks; with last dose administered at Week 72), and a Follow-up period of at least 2 years.","CASTING was a prospective, international, multicenter, single-arm, open-label phase 3b trial evaluating the efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis who had a suboptimal response to one or two prior disease-modifying therapies. Patients received intravenous ocrelizumab 600 mg every 24 weeks for 96 weeks. The primary endpoint was the proportion of patients achieving no evidence of disease activity (NEDA), defined as absence of relapses, disability progression, and inflammatory MRI measures, with prespecified MRI re-baselining at Week 8. The study hypothesis was that switching to ocrelizumab would result in high NEDA rates in this population with prior treatment failure.",True,0.94,success,BriefSummary,protocolSection.descriptionModule.briefSummary,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.descriptionModule.detailedDescription,EV,EV,,"CASTING (NCT02861014) was designed specifically for patients with relapsing-remitting multiple sclerosis (RRMS) with a suboptimal response to one or two prior disease-modifying therapies (DMTs). Eligibility criteria included age 18-55 years, EDSS score 0.0-4.0, disease duration <10 years from first symptom, and prior suboptimal response defined as one or more relapses, one or more T1-weighted contrast-enhancing lesions, or two or more new/enlarging T2-weighted hyperintense lesions on MRI while receiving a stable dose of DMT for at least 6 months. Patients could be enrolled based on MRI criteria only. The study enrolled 680 patients across 157 centers in 16 countries across Europe and Turkey from September 2016 to October 2019. Patients received ocrelizumab 600 mg intravenously every 24 weeks for 96 weeks (first dose administered as two 300-mg infusions, 14 days apart). The primary endpoint was no evidence of disease activity (NEDA) at Week 96, incorporating MRI re-baselining at Week 8 to exclude MRI activity occurring during the first 8 weeks before the potential treatment benefit of ocrelizumab is realized. NEDA was defined as absence of protocol-defined relapse, 24-week confirmed disability progression, contrast-enhancing lesions, and new/enlarging T2-weighted hyperintense lesions. Secondary endpoints included NEDA rates at 24 and 48 weeks, time to first event of disease activity, annualized relapse rate, MRI measures including lesion counts and volumes, and brain volume changes. Safety assessments included adverse events, serious adverse events, laboratory tests, and vital signs. The study incorporated subgroup analyses by demographics, disease characteristics, reason for enrollment, and prior DMT exposure.",,,,DetailedDescription,protocolSection.descriptionModule.detailedDescription,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.conditionsModule.conditions,TP,TP,"['Multiple Sclerosis, Relapsing-Remitting']","['Multiple Sclerosis, Relapsing-Remitting', 'Relapsing-Remitting Multiple Sclerosis', 'RRMS']",True,1.0,superset,Condition,protocolSection.conditionsModule.conditions,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.conditionsModule.keywords,EV,EV,,"['Multiple Sclerosis', 'Relapsing-Remitting', 'Ocrelizumab', 'Disease-Modifying Therapy', 'DMT', 'Suboptimal Response', 'Treatment Failure', 'No Evidence of Disease Activity', 'NEDA', 'Magnetic Resonance Imaging', 'MRI Re-baselining', 'B-cell Depletion', 'CD20', 'Disability Progression', 'Relapse', 'Contrast-Enhancing Lesions', 'Brain Volume', 'EDSS', 'Expanded Disability Status Scale', 'Phase 3b Trial']",,,,Keyword,protocolSection.conditionsModule.keywords,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.studyType,TP,TP,INTERVENTIONAL,INTERVENTIONAL,True,1.0,exact,StudyType,protocolSection.designModule.studyType,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.patientRegistry,EV,EV,,False,,,,PatientRegistry,protocolSection.designModule.patientRegistry,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.phases,TP,TP,['PHASE3'],['PHASE3'],True,1.0,exact,Phase,protocolSection.designModule.phases,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.allocation,TP,TP,NA,NA,True,1.0,exact,DesignAllocation,protocolSection.designModule.designInfo.allocation,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.interventionModel,TP,TP,SINGLE_GROUP,SINGLE_GROUP,True,1.0,exact,DesignInterventionModel,protocolSection.designModule.designInfo.interventionModel,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.interventionModelDescription,EV,EV,,"CASTING was a prospective, international, multicenter, single-arm, open-label phase 3 trial. Patients received intravenous ocrelizumab 600 mg every 24 weeks for 96 weeks (first dose administered as two 300-mg infusions, 14 days apart).",,,,DesignInterventionModelDescription,protocolSection.designModule.designInfo.interventionModelDescription,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.masking,TP,TP,NONE,NONE,True,1.0,exact,DesignMasking,protocolSection.designModule.designInfo.maskingInfo.masking,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,EV,EV,,"Open-label study with no masking. All participants, care providers, investigators, and outcomes assessors were aware of the treatment assignment.",,,,DesignMaskingDescription,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.enrollmentInfo.count,TP,TP,681,680,True,0.95,success,EnrollmentCount,protocolSection.designModule.enrollmentInfo.count,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[11].description,EV,EV,,Change in total T2-weighted hyperintense lesion volume from Week 8 to Week 96.,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[18].description,EV,EV,,"Percentage change in WBV from Week 8, assessed using SIENA/X.",,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[19].description,EV,EV,,"Percentage change in CGMV from Week 8, assessed using paired Jacobian integration.",,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[20].description,EV,EV,,"Percentage change in WMV from Week 8, assessed using paired Jacobian integration.",,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[6].description,EV,EV,,ARR was calculated as the total number of protocol-defined relapses for all patients divided by the total patient-years of exposure to treatment.,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[7].description,EV,EV,,24-week CDP was defined as an increase in EDSS score from baseline of at least 1.0 point.,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[9].description,EV,EV,,Time to occurrence of first new and/or enlarging T2-weighted hyperintense lesion detected on MRI from Week 8 baseline.,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[0].measure,EV,EV,,Proportion of patients with NEDA during the treatment period (MRI from screening),,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[1].measure,EV,EV,,Predictors of NEDA,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[2].measure,EV,EV,,Association of NEDA with disability or other efficacy variables,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[3].measure,EV,EV,,Epoch analysis of NEDA (Year 1 and Year 2),,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[4].measure,EV,EV,,Proportion of patients with NEDA by number of prior DMTs,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[5].measure,EV,EV,,Safety outcomes: incidence and nature of adverse events (AEs) and serious adverse events (SAEs),,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[0].description,EV,EV,,"Exploratory analysis of NEDA without MRI re-baselining at Week 8, using MRI from screening as baseline.",,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[1].description,EV,EV,,"Exploratory analysis to identify baseline factors prognostic for NEDA at Week 96, using a logistic regression model.",,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[2].description,EV,EV,,Exploratory analysis of the association between NEDA status and disability or other efficacy measures.,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[3].description,EV,EV,,Exploratory analysis of NEDA during Year 1 (Weeks 0–48) and Year 2 (Weeks 48–96).,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[4].description,EV,EV,,Post-hoc analysis of NEDA rates in patients who received 1 versus 2 prior DMTs (with MRI re-baselining at Week 8).,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[5].description,EV,EV,,"Incidence and nature of AEs and SAEs, including infusion-related reactions, infections, neoplasms, and other safety events.",,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[0].timeFrame,EV,EV,,Up to 96 weeks,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[1].timeFrame,EV,EV,,96 weeks,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[2].timeFrame,EV,EV,,96 weeks,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[3].timeFrame,EV,EV,,Year 1 (Weeks 0–48) and Year 2 (Weeks 48–96),,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[4].timeFrame,EV,EV,,96 weeks,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[5].timeFrame,EV,EV,,Up to 96 weeks (treatment period) and safety follow-up (up to 96 additional weeks),,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.eligibilityCriteria,TP,TP,"Inclusion Criteria:

* Have a definite diagnosis of RRMS, confirmed as per the revised McDonald 2010 criteria
* Have a length of disease duration, from first symptom, of less than (\<) 10 years
* Have received no more than two prior DMTs, and the discontinuation of the most recent DMT was due to lack of efficacy
* Suboptimal disease control while on a DMT
* Expanded Disability Status Scale (EDSS) of 0.0 to 4.0, inclusive, at Screening
* For women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 6 months after the last dose of study drug

Exclusion Criteria:

* Secondary progressive multiple sclerosis (SPMS) or history of primary progressive or progressive relapsing multiple sclerosis (MS)
* Inability to complete an Magnetic Resonance Imaging (MRI) procedure
* Known presence of other neurological disorders
* Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
* History or currently active primary or secondary immunodeficiency
* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
* History of opportunistic infections
* History or known presence of recurrent or chronic infection
* History of malignancy
* Congestive heart failure
* Known active bacterial, viral, fungal, mycobacterial infection or other infection, excluding fungal infection of nail beds","**Inclusion Criteria:**

- Age 18-55 years
- Diagnosis of relapsing-remitting multiple sclerosis (RRMS) according to the McDonald 2010 criteria
- Expanded Disability Status Scale (EDSS) score of 0.0-4.0 inclusive at screening
- Disease duration < 10 years from first symptom (if date of first symptom was unknown, then the diagnosis of RRMS was ≤ 5 years prior to enrollment)
- Prior suboptimal response to one or two disease-modifying therapies (DMTs), defined as:
  - One or more clinically reported relapse(s); OR
  - One or more T1-weighted contrast-enhancing lesion(s) (CELs); OR
  - Two or more new and/or enlarging T2-weighted hyperintense lesions on MRI
  - While receiving a stable dose of that DMT for at least 6 months
- In patients receiving stable doses of the same approved DMT for more than 1 year, at least one of the above events must have occurred within the last 12 months of treatment with this DMT
- Adequate washout period from prior DMT as guided by local prescribing labels

**Exclusion Criteria:**

- Previous treatment with natalizumab (to avoid risk of progressive multifocal leukoencephalopathy), unless natalizumab was discontinued because of persistent anti-natalizumab antibodies
- Patients withdrawn from DMTs for the sole purpose of participation in the study",True,0.83,success,EligibilityCriteria,protocolSection.eligibilityModule.eligibilityCriteria,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.healthyVolunteers,TP,TP,False,False,True,1.0,exact,HealthyVolunteers,protocolSection.eligibilityModule.healthyVolunteers,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.sex,TP,TP,ALL,ALL,True,1.0,exact,Sex,protocolSection.eligibilityModule.sex,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.minimumAge,TP,TP,18 Years,18 Years,True,1.0,exact,MinimumAge,protocolSection.eligibilityModule.minimumAge,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.maximumAge,TP,TP,55 Years,55 Years,True,1.0,exact,MaximumAge,protocolSection.eligibilityModule.maximumAge,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.stdAges,TP,TP,['ADULT'],['ADULT'],True,1.0,exact,StdAge,protocolSection.eligibilityModule.stdAges,False,True,True,False,True,False
